Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Subcutaneous LY3819253 (Bamlanivimab) in Healthy Participants
NCT04537910Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bamlanivimab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) at Day 85. Started Sep 2020; status: completed.
02
Drugs
bamlanivimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04537910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537910.